-

ORGO SHAREHOLDERS: Robbins LLP Informs Investors of Class Action Against Organogenesis Holdings, Inc. (ORGO)

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Organogenesis Holdings, Inc. (NASDAQ: ORGO) securities between March 17, 2021 and October 11, 2021, for violations of the Securities Exchange Act of 1934. Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets in the U.S.

If you suffered a loss due to Organogenesis Holdings, Inc.'s misconduct, click here.

Organogenesis Holdings, Inc. (ORGO) Failed to Disclose the Truth About its High Prices and Product Reimbursements

According to the complaint, during the class period, Defendants improperly billed the federal government for its Affinity and PuraPly XT products by setting the price for those products multiple times higher than similar products and improperly inducing doctors to use its Affinity and PuraPly XT products through lucrative reimbursements. As a result, the Company's revenue and profits derived from its Affinity and PuraPly XT products were in substantial part unsustainable.

The truth came out on October 12, 2021, in an anonymous report published on Value Investors Club, an online website where investors share investment advice. On this news, Organogenesis' stock price fell over 14%, to close at $10.35 per share on October 12, 2021.

If you acquired shares of Organogenesis Holdings, Inc. (ORGO) securities between March 17, 2021 and October 11, 2021, you have until February 8, 2022, to ask the court to appoint you lead plaintiff for the class.

Representation is on a contingency fee basis. Shareholders pay no fees or costs.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Organogenesis Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investment Notice: Robbins LLP Informs Investors of the Megan Holdings Limited Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Megan Holdings Limited (NASDAQ: MGN) securities between September 26, 2025 and March 25, 2026, or acquired shares in connection with its initial public offering ("IPO") on September 26, 2025. The Company conducts its purported business operations in Malaysia and purportedly is principally engaged in the development, construction, and maintenanc...

Investor Notice: Robbins LLP Informs Investors of the Photronics, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Photronics, Inc. (NASDAQ: PLAB) securities between December 10, 2025 and May 27, 2026. Photronics is a global manufacturer of photomasks, which are microscopic circuit patterns contained on very precise glass or quartz plates, and which are a necessary element in the manufacturing of integrated circuits (“ICs”) and flat panel displays (“FPDs”)....

Investor Notice: Robbins LLP Informs Investors of the Insulet Corporation Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the U.S. and internationally. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The A...
Back to Newsroom